Literature DB >> 28786074

Akt Inhibitor Perifosine Prevents Epileptogenesis in a Rat Model of Temporal Lobe Epilepsy.

Feng Zhu1, Jiejing Kai1,2, Linglin Chen1,2, Meiling Wu1, Jingyin Dong1, Qingmei Wang1,2, Ling-Hui Zeng3,4.   

Abstract

Accumulating data have revealed that abnormal activity of the mTOR (mammalian target of rapamycin) pathway plays an important role in epileptogenesis triggered by various factors. We previously reported that pretreatment with perifosine, an inhibitor of Akt (also called protein kinase B), abolishes the rapamycin-induced paradoxical increase of S6 phosphorylation in a rat model induced by kainic acid (KA). Since Akt is an upstream target in the mTOR signaling pathway, we set out to determine whether perifosine has a preventive effect on epileptogenesis. Here, we explored the effect of perifosine on the model of temporal epilepsy induced by KA in rats and found that pretreatment with perifosine had no effect on the severity or duration of the KA-induced status epilepticus. However, perifosine almost completely inhibited the activation of p-Akt and p-S6 both acutely and chronically following the KA-induced status epilepticus. Perifosine pretreatment suppressed the KA-induced neuronal death and mossy fiber sprouting. The frequency of spontaneous seizures was markedly decreased in rats pretreated with perifosine. Accordingly, rats pretreated with perifosine showed mild impairment in cognitive functions. Collectively, this study provides novel evidence in a KA seizure model that perifosine may be a potential drug for use in anti-epileptogenic therapy.

Entities:  

Keywords:  Akt-mTOR signaling; Cognitive function; Kainic acid; Perifosine; Spontaneous seizure

Mesh:

Substances:

Year:  2017        PMID: 28786074      PMCID: PMC5856709          DOI: 10.1007/s12264-017-0165-7

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  38 in total

1.  Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy.

Authors:  X Huang; J McMahon; Y Huang
Journal:  Neuroscience       Date:  2012-04-20       Impact factor: 3.590

2.  The relationship of seizure focus with depression, anxiety, and health-related quality of life in children and adolescents with epilepsy.

Authors:  William A Schraegle; Jeffrey B Titus
Journal:  Epilepsy Behav       Date:  2017-01-28       Impact factor: 2.937

Review 3.  mTOR inhibition in epilepsy: rationale and clinical perspectives.

Authors:  Adam P Ostendorf; Michael Wong
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

4.  A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

Authors:  Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Oren J Becher; Ellen M Basu; Stephen S Roberts; Kim Kramer; Ira J Dunkel
Journal:  Int J Cancer       Date:  2016-09-30       Impact factor: 7.396

Review 5.  In focus: The everyday lives of families of adult individuals with epilepsy.

Authors:  Fahed Saada; Zizhao Selina Wang; Ramon Edmundo D Bautista
Journal:  Epilepsy Behav       Date:  2015-06-17       Impact factor: 2.937

6.  Mossy fiber synaptic reorganization induced by kindling: time course of development, progression, and permanence.

Authors:  J E Cavazos; G Golarai; T P Sutula
Journal:  J Neurosci       Date:  1991-09       Impact factor: 6.167

7.  PI3K-Akt signaling activates mTOR-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy.

Authors:  Yevgeny Berdichevsky; Alexandra M Dryer; Yero Saponjian; Mark M Mahoney; Corrin A Pimentel; Corrina A Lucini; Marija Usenovic; Kevin J Staley
Journal:  J Neurosci       Date:  2013-05-22       Impact factor: 6.167

Review 8.  Mammalian target of rapamycin (mTOR) pathways in neurological diseases.

Authors:  Michael Wong
Journal:  Biomed J       Date:  2013 Mar-Apr       Impact factor: 4.910

9.  Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy.

Authors:  Paul S Buckmaster; Elizabeth A Ingram; Xiling Wen
Journal:  J Neurosci       Date:  2009-06-24       Impact factor: 6.167

10.  Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up.

Authors:  Daniel Ebrahimi-Fakhari; Cornelia Sigrid Lissi Müller; Sascha Meyer; Marina Flotats-Bastardas; Thomas Vogt; Claudia Pföhler
Journal:  Dermatol Ther (Heidelb)       Date:  2017-02-08
View more
  5 in total

Review 1.  Expression and Function of Zinc-α2-Glycoprotein.

Authors:  Xin Wei; Xi Liu; Changhong Tan; Lijuan Mo; Hui Wang; Xi Peng; Fen Deng; Lifeng Chen
Journal:  Neurosci Bull       Date:  2019-01-04       Impact factor: 5.203

2.  Inhibition of AKT/GSK3β/CREB Pathway Improves the Responsiveness to AMPA Receptor Antagonists by Regulating GRIA1 Surface Expression in Chronic Epilepsy Rats.

Authors:  Ji-Eun Kim; Duk-Shin Lee; Hana Park; Tae-Hyun Kim; Tae-Cheon Kang
Journal:  Biomedicines       Date:  2021-04-14

3.  Rapamycin, but not minocycline, significantly alters ultrasonic vocalization behavior in C57BL/6J pups in a flurothyl seizure model.

Authors:  Samantha L Hodges; Paige D Womble; Eliesse M Kwok; Alyssa M Darner; Savannah S Senger; Matthew S Binder; Amanda M Faust; Siena M Condon; Suzanne O Nolan; Saul I Quintero; Joaquin N Lugo
Journal:  Behav Brain Res       Date:  2021-04-25       Impact factor: 3.352

4.  Fangjing decoction relieves febrile seizures-induced hippocampal neuron apoptosis in rats via regulating the Akt/mTOR pathway.

Authors:  Xian-Ke Xu; Sun-Yao Wang; Ying Chen; Lu Zhan; Zheng-Yang Shao; Long Lin; Wei-Chao Yan; Shu-Fen Mei
Journal:  Biosci Rep       Date:  2018-10-31       Impact factor: 3.840

Review 5.  Multiple Facets of Autophagy and the Emerging Role of Alkylphosphocholines as Autophagy Modulators.

Authors:  Ferda Kaleağasıoğlu; Doaa M Ali; Martin R Berger
Journal:  Front Pharmacol       Date:  2020-04-29       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.